10-Q: Vivani Medical Reports Q2 2024 Results, Advances GLP-1 Implant Programs

Vivani Medical reported its Q2 2024 financial results and provided updates on its GLP-1 implant programs, including the lifting of a clinical hold and a strategic shift towards obesity treatments.

Summary

• Vivani Medical, a preclinical stage biopharmaceutical company, released its financial results for the second quarter of 2024.
• The company is focused on developing miniaturized, subdermal implants using its NanoPortal technology for long-term drug delivery.
• Vivani's lead program, NPM-115, is a six-month GLP-1 implant candidate for chronic weight management.
• The company is also developing NPM-139, a GLP-1 implant with potential for once-yearly administration.
• A clinical hold on NPM-119, a GLP-1 implant for type 2 diabetes, was lifted by the FDA in June 2024.
• Vivani has shifted its focus to prioritize its obesity portfolio, with preclinical data showing comparable weight loss to semaglutide.
• The company reported a net loss of $5.356 million for the three months ended June 30, 2024, and $11.395 million for the six months ended June 30, 2024.
• Vivani's cash and cash equivalents totaled $24.919 million as of June 30, 2024.
• The company estimates its current cash will fund operations into the second half of 2025.

Sentiment

Score: 5

Explanation: The document presents a mixed picture. While there are positive developments such as the lifting of the clinical hold and promising preclinical data, the company is still in a pre-revenue stage with significant losses and a reliance on external funding. The strategic shift towards obesity is positive, but the company faces risks related to clinical trials, regulatory approvals, and ongoing litigation.

Positives

• The FDA lifted the clinical hold on NPM-119, allowing the company to move forward with human trials.
• Preclinical data shows the company's exenatide implant achieves weight loss comparable to semaglutide.
• The company has secured additional funding through a securities purchase agreement and a sales agreement.
• Vivani is strategically prioritizing its obesity portfolio, which has significant market potential.
• The LIBERATE-1 study is being redesigned to focus on obese and overweight patients, aligning with the company's strategic shift.

Negatives

• The company reported a net loss of $5.356 million for the three months ended June 30, 2024, and $11.395 million for the six months ended June 30, 2024.
• Vivani has incurred recurring operating losses and negative operating cash flows since inception.
• The company is dependent on raising additional capital to continue operations.
• There is ongoing litigation with Pixium Vision SA, with a decision expected in September 2024.
• The company has no revenue and is reliant on external funding.

Risks

• The company's ability to continue as a going concern is dependent on raising additional capital and/or developing profitable operations.
• Clinical trials are expensive and have uncertain outcomes, with potential for delays or negative results.
• Regulatory approvals are not guaranteed, and the company may face challenges in obtaining them.
• The company is subject to risks associated with developing novel pharmaceutical products and medical devices.
• There is a risk of not being able to attract research analysts due to the company becoming public through a merger rather than an IPO.
• The company is involved in ongoing litigation with Pixium Vision SA, which could result in additional costs and impact operations.

Future Outlook

Vivani estimates that its current cash will provide sufficient funds to meet its planned obligations into the second half of 2025. The company plans to initiate the LIBERATE-1 study in Australia in the fourth quarter of 2024, with data expected in 2025.

Management Comments

• Vivanis main priority is the further development of the companys lead program NPM115 , a miniature, 6 -month, GLP1 implant candidate for chronic weight management.
• Vivanis management team remains committed to identifying and exploring strategic options that will enable further development of its pioneering neurostimulation systems from legacy company Second Sight.
• Moving forward, Vivanis focus will be on the further development of NPM115 and its emerging pipeline of innovative miniature, long-term drug implants to treat patients with chronic diseases and high unmet medical need.

Industry Context

The company's focus on GLP-1 implants aligns with the growing market for obesity and diabetes treatments. The shift towards long-acting implants addresses the issue of medication non-adherence, a significant problem in chronic disease management. The company's technology aims to minimize fluctuations in drug levels, potentially improving tolerability profiles for medicines like GLP-1 receptor agonists.

Comparison to Industry Standards

• Vivani's preclinical weight loss data for its exenatide implant is compared to semaglutide, the active ingredient in Ozempic/Wegovy, which are established treatments in the obesity market.
• The company's focus on long-acting implants is a direct response to the high discontinuation rates observed with injectable GLP-1 therapies like Wegovy, where 64% of patients discontinue within the first year.
• The company's NanoPortal technology aims to provide a more consistent drug delivery profile than traditional injectable or oral medications, which is a key differentiator in the market.
• The company's development of a once-yearly GLP-1 implant (NPM-139) is a significant advancement compared to current weekly or daily treatments, potentially offering a more convenient option for patients.
• The company's approach to drug delivery is similar to other companies developing long-acting implantable drug delivery systems, but Vivani's NanoPortal technology is a unique approach.

Management Changes

Legal Proceedings

• One opposition filed by Pixium Vision SA is pending in the European Patent Office challenging the validity of a European patent owned by Cortigent.
• The company is involved in ongoing litigation with Pixium Vision SA related to a terminated Memorandum of Understanding, with a decision expected on September 10, 2024.

Related Party Transactions

• Vivani has agreed to advance funds and provide services to Cortigent, a wholly owned subsidiary, until the earlier of December 31, 2024, or the closing of an initial public offering of Cortigent.
• Cortigent has agreed to repay $1,500,000 to Vivani at the conclusion of the Funding Support Term and will enter into a five-year promissory note at 5% interest for $2,000,000 in favor of Vivani.

Stakeholder Impact

• Shareholders face the risk of dilution from future equity offerings.
• Employees may be affected by potential changes in staffing levels.
• Patients could benefit from the development of new long-acting drug delivery options.
• The company's success is dependent on the support of its suppliers and partners.
• Creditors face the risk of non-payment if the company is unable to raise additional capital.

Next Steps

• Initiate the LIBERATE-1 study in Australia in the fourth quarter of 2024.
• Continue development of NPM-115 and other GLP-1 implant candidates.
• Explore strategic options for the neurostimulation division.
• Seek regulatory approvals for product candidates.
• Continue to raise additional capital to fund operations.

Key Dates

Keywords

GLP-1 implant, obesity, weight management, drug delivery, subdermal implant, NanoPortal technology, clinical trials, pharmaceutical, biopharmaceutical, exenatide, semaglutide, type 2 diabetes, medication adherence